Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

GMABGenmabNot started yet

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer

Ovarian Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 3
Patients
602 (planned)
Started
Nov 2026
Main results expected
Mar 2030
Fully finished
Jul 2034
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Progression-free Survival (PFS), per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, as Determined by Blinded Independent Central Review (BICR)

    Measured over: Approximately 2 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT07859215 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07859215) ↗